We examined integrase-defective lentiviral vectors (IDLVs) with a mutant (D64V) integrase in terms of their residual integration capability, the levels and duration of transgene expression and their therapeutic potential in comparison to wild-type lentiviral vectors (WTLVs) with a wild-type integrase gene. Compared with WTLVs, the IDLV-mediated proviral integration into host-cell chromosomes was approximately 1/3850 in HeLa cells and approximately 1/111 in mouse cerebellar neurons in vivo. At 2 months, transgene expression by IDLVs in the mouse cerebellum was comparable to that by WTLVs, but then significantly decreased. The mRNA levels at 6 and 12 months after injection in IDLV-infected cerebella were approximately 26% and 5%, respectively, of the mRNA levels in WTLV-injected cerebella. To examine the therapeutic potential, IDLVs or WTLVs expressing a molecule that enhances the ubiquitin-proteasome pathway were injected into the cerebella of spinocerebellar ataxia type 3 model mice (SCA3 mice). IDLV-injected SCA3 mice showed a significantly improved rotarod performance even at 1 year after-injection.
INTRODUCTION
Lentiviral vectors enable efficient, long-lasting and stable transgene expression in both dividing and quiescent cells, including postmitotic neurons.
1,2 Therefore, they are promising as therapeutic gene transfer vectors. Efficient and sustained expression of a transgene is mediated by the insertion of a proviral genome into host-cell chromosomes. 3, 4 However, the random insertion of proviruses, called 'insertional mutagenesis', may disrupt critical genes, such as tumor suppressor genes and those of protein kinases/phosphatases, which potentially causes oncogenic transformation or cell death. [5] [6] [7] The proviral insertion into host-cell chromosomes is mediated by a viral integrase. To avoid insertional mutagenesis, integrasedefective lentiviral vectors (IDLVs) have been developed, in which mutations were introduced in the coding sequence for the integrase gene or at sites in the viral genome where the integrase attaches and mediates insertion (att sites). [8] [9] [10] [11] [12] [13] [14] Unintegrated provirus from IDLVs resides in the nucleus as an episomal form and expresses a transgene for at least several months in neuronal cells.
14 Thus, IDLVs are safer and promising gene therapy vectors for future clinical applications. Nonetheless, several issues remain to be clarified in IDLVs, including the amount of transgene expressed by IDLVs compared with wild-type lentiviral vectors (WTLVs); how long transgene expression continues and whether the therapeutic effect of IDLVs for gene therapy is comparable to WTLVs.
In this study, we explored the temporal change in expression levels of a transgene by IDLVs, relative to WTLVs, for up to 1 year. Moreover, the usefulness of IDLVs as gene therapy vectors was evaluated by examining the behavioral recovery of spinocerebellar ataxia type 3 model mice (SCA3 mice) after injection of IDLVs or WTLVs expressing the therapeutic protein CRAG (collapsin response mediator protein-associated molecule-associated guanosine triphosphatase). 15, 16 
RESULTS

Generation of lentiviral vectors with a class I integrase mutation
We used a class I integrase mutation to generate the IDLVs expressing green fluorescent protein (GFP) or GFP-P2A-CRAG under the control of the murine stem cell virus (MSCV) promoter (Figures 1a and b) . This mutation had no influence on reverse transcription, nuclear import of the preintegration complex or circularization of the viral genome in the nucleus.
No influence of the integrase mutation on the production of IDLVs in HEK293T cells To examine whether mutation in the integrase gene affected production of viral vectors, IDLVs and WTLVs were simultaneously produced using the same protocol. The genomic titers were determined by quantitative reverse transcriptase-PCR using four batches each of IDLVs and WTLVs. The genomic titers of WTLVs and IDLVs were 1.42 ± 0.18 × 10 11 and 1.47 ± 0.29 × 10 11 vector genomes (vg) ml − 1 , respectively, and there was no significant difference between the two groups ( Figure 1c) . We also assessed the amounts of virion particles of IDLVs and WTLVs, both of which were obtained from four independent cultures by western blotting using an antibody against the envelope glycoprotein, vesicular stomatitis virus-G protein (VSV-G). The band intensities for VSV-G on the blot were comparable between WTLVs and IDLVs ( Figure 1d ). These results indicate that the integrase mutation did not affect the production of lentiviral vector particles in human embryonic kidney 293T (HEK293T) cells.
Drastic reduction of chromosomal integration of proviruses from IDLVs We next examined the integration of the proviral genome derived from IDLVs or WTLVs into chromosomes of HeLa cells or mouse cerebellar cells in vivo. HeLa cells cultured in a 6-cm dish were infected with 1 μl of WTLVs or a same volume of IDLVs with the same titer. The cells were collected at 4 days after lentiviral infection, and real-time quantitative Alu-PCR was performed. The integration efficiency of IDLVs was significantly reduced to 1/3850 compared with WTLVs; the ratio of proviral integration by IDLVs to that by WTLVs was 2.6 ± 0.6 × 10 − 4 (P o 0.01, n = 8 culture pairs) (Figure 1e ).
Then, we examined the efficiency of proviral integration by IDLVs in vivo. Ten μl of the IDLVs (1.47 × 10 11 vg ml
) or the same volume of WTLVs (1.42 × 10 11 vg ml − 1 ) that expressed GFP under the control of the MSCV promoter was injected into postnatal day (P) 27 or P28 mouse cerebellum (five mice, each). At 1 week after the viral injection, GFP-expressing cerebellar tissue was resected under a fluorescence stereoscopic microscope. Subsequently, the integrated proviral genome was quantified by real-time quantitative B1-PCR (see the Materials and Methods section). The integration efficiency of IDLVs in the cerebellum in vivo was significantly reduced to o 1/100 of WTLVs (P o0.001) (Figure 1f) . Thus, the D64V mutation in the integrase significantly prevented IDLVs from proviral integration into host-cell genomes in both cultured cells and the cerebellum in vivo.
Spatiotemporal change in the expression of GFP by IDLVs and WTLVs We found that the efficiency of proviral integration by IDLVs in the cerebellum in vivo was o1/100 of that by WTLVs. We next compared the spatial and temporal profiles of GFP expression by IDLVs in the cerebellum in vivo with those by WTLVs up to 1 year after the viral injection. Ten μl of WTLVs (1.47 × 10 11 vg ml − 1 ) or the same volume of WTLVs (2.69 × 10 11 vg ml − 1 ) was injected into the mouse cerebella as described in the Materials and methods section. The mice were killed at 2, 6 and 12 months after the viral injection. At 2 and 6 months after the viral injection, the gross GFP fluorescence emitted from the whole cerebella, which was detected under a fluorescence stereoscopic microscope, was approximately the same between IDLVs and WTLVs (Figures 2a, b , g and h). At 1 year after viral injection, the GFP fluorescent area on the IDLV-treated (Figure 2i ), but not the fluorescent area on the WTLV-treated (Figure 2c ), cerebellum was markedly decreased.
Sagittal sections of the cerebellar vermis that received injection of WTLVs or IDLVs showed GFP expression primarily in Purkinje cells (PCs) and less efficiently in interneurons in the molecular IDLVs and WTLVs (four batches each) were produced using the same protocol. Genomic titers were measured by quantitative PCR, whereas the amounts of IDLV and WTLV particles obtained from four independent cultures, respectively, were examined by western blotting using antibodies against the envelope glycoprotein VSV-G. There was no statistically significant difference (ns) between the two groups. (e and f) Drastic reduction of proviral integration by IDLVs, compared with WTLVs, in cultured HeLa cells (e) or mouse cerebellum in vivo (f). Proviral integration into the host chromosome was examined by real-time quantitative Alu-PCR or B1-PCR. In each group, four (e) or five (f) independent experiments were conducted. **P o 0.01 and ***P o 0.001 by Tukey's post hoc test after one-way analysis of variance (ANOVA).
layer (Figures 2d, f and j-l). Because the GFP fluorescence images of the cerebellar cortex were obtained from the efficiently transduced areas close to the viral injection site, GFP expression in PCs appears to be maintained even 12 months after the IDLVs injection (Figure 2l ).
GFP fluorescence intensity in the PC somata was quantitatively examined in the cerebella treated with IDLVs or WTLVs, and the GFP fluorescence levels resulting from IDLVs were expressed as the ratio relative to those resulting from WTLVs. GFP fluorescence intensity in PCs transduced by IDLVs was approximately 93% of that observed in WTLV-transduced cells at 2 months after the injection, and there was no statistically significant difference in GFP fluorescence intensity in the PC somata between IDLV-and WTLV-treated mice. However, the GFP fluorescence intensity was significantly reduced to 87% (Po 0.05) and 49% (Po 0.001) of that by WTLVs at 6 and 12 months after the injection, respectively (Figure 2m) .
The temporal change in the expression levels of GFP mRNA in IDLV-treated cerebella compared with WTLV-treated cerebella was further assessed by quantitative PCR. The cerebellar vermis was excised from IDLV-and WTLV-treated cerebella at 2, 6 and 12 months after the injection. The amount of GFP mRNA in the IDLV-treated cerebella was comparable to that in the WTLVtreated cerebella at 2 months, but significantly decreased to approximately 25% at 6 months (P o 0.001) and o 5% at 12 months after the viral injection (Po 0.001) (Figure 2n ).
Restoration of rotarod performance in SCA3 mice treated with IDLVs expressing CRAG Previously, we injected WTLVs expressing CRAG into the cerebellar cortex of ataxic SCA3 mice that expressed mutant ataxin-3 under the control of the PC-specific L7 promoter. 16 Expression of CRAG caused degradation of mutant ataxin-3 aggregates in PCs through the ubiquitin-proteasome pathway, 15 resulting in a rescue of the ataxia phenotype. Then, using this system, we examined the therapeutic efficacy of IDLVs for up to 1 year after the injection. Ten microliters of WTLVs (over 1.0 × 10 10 transduction units/ml − 1 , which corresponds roughly to 1.0 × 10 11 vg ml − 1 or higher) or IDLVs with the similar genome titer, both of which expressed GFP-P2A-CRAG, were injected into 3-week-old SCA3 mice, and the rotarod performance was examined immediately before and at 2, 6 and 12 months after the viral injection.
In the accelerating protocol (Figure 3a ), untreated SCA3 mice stayed on the rod only for approximately 20 s, and the time gradually decreased to approximately 10 s at 1 year of age. The SCA3 mice that received an injection of IDLVs expressing GFP alone showed a rotarod performance approximately the same as non-injected SCA3 mice at up to 12 months after the viral injection. In contrast, a significantly better rotarod performance was observed in the SCA3 mice that received an injection of IDLVs expressing GFP-P2A-CRAG at 2 (P o0.05) and 6 (P o 0.01) months after the viral injection compared with non-injected control SCA3 . GFP expression in the cerebella was examined at 2 (upper images), 6 (middle images) and 12 months (lower images) after injection. (m) Change in the GFP fluorescence intensity in PC somata at 2, 6 and 12 months after the viral injection. GFP fluorescence intensity in more than 100 PCs was measured from three WTLV-treated and three IDLV-treated cerebella, and the % ratio of the intensity in IDLV-infected PCs compared with that in WTLV-infected PCs was expressed. (n) Change in the levels of GFP mRNA in the cerebellar cortex at 2, 6 and 12 months after the viral injection. The cerebellar vermis was excised from WTLV-and IDLV-treated cerebella, and GFP mRNA was measured by quantitative PCR. The ratio of the levels of GFP mRNA in IDLV-infected tissue to those in WTLVinfected tissues was expressed. *P o0.05 and ***Po 0.001 by an unpaired t-test. ns, not significant. Scale bar, 100 μm.
mice. The performance became worse at 12 months after the injection, but still remained significantly better (P o0.05) than that of the non-injected control SCA3 mice. SCA3 mice that expressed GFP-P2A-CRAG from WTLVs showed a similar time course as those expressing GFP-P2A-CRAG from IDLVs. However, their performance was indistinguishable from that of non-injected SCA3 mice at 12 months after the injection. Similarly, in the constant speed protocol (Figure 3b ), the injection of IDLVs expressing GFP-P2A-CRAG, but not GFP alone, significantly improved rotarod performance at 2 (P o 0.001), 6 (P o0.01) and 12 (P o0.05) months after the viral injection compared with non-injected SCA3 mice. SCA3 mice expressing GFP-P2A-CRAG by WTLVs also showed better performance than non-injected SCA3 mice at 2 (P o 0.01) and 6 (P o 0.05) months after the injection; however, similar to the accelerating paradigm, their performance was indistinguishable from that of non-injected SCA3 mice at 12 months after the injection.
Significant decrease of the mutant ataxin-3 aggregates by IDLVs expressing CRAG Viral vector-injected SCA3 mice and non-injected transgenic littermates were killed to examine the effect of CRAG expression on ataxin-3 aggregates in PCs. We examined only the GFP-positive area because GFP-negative areas that had once expressed CRAG from IDLVs and regressed the expression thereafter were indistinguishable from non-infected areas. Thus, although the expression levels of GFP-P2A-CRAG appear similar between WTLV- (Figure 4b ) and IDLV-treated (Figure 4c ) groups, the GFPexpressing areas were indeed significantly limited in the IDLVtreated cerebella as presented in Figure 2i . Immunohistochemistry for HA tagged with mutant ataxin-3 and calbindin showed numerous large aggregates along the disrupted PC layer in noninjected SCA3 mice (Figures 4a, d, g and j) , whereas the number and the size of the aggregates along the PC layer decreased in SCA3 mice expressing CRAG from WTLVs (Figures 4b, e, h and k) or IDLVs (Figures 4c, f, I and l) .
We counted the number of PCs along more than 100 μm length of the PC layer from non-injected SCA3 mice and mice expressing CRAG by WTLVs or IDLVs (more than three mice in each group). The average number of PCs per 100 μm length of the PC layer, which was visualized by immunolabeling for calbindin, was not significantly different between non-injected SCA3 mice (6.3 ± 0.5 PCs) and mice treated with WTLVs (7.8 ± 1.1 PCs) or IDLVs (7.8 ± 0.7 PCs) expressing CRAG (Figure 4m ). We confirmed that the density of transduced PCs in the regions examined was approximately the same between WTLV-and IDLV-treated SCA3 mice (Figure 4n ). Then, we counted the number of aggregates with a diameter over 10 μm 2 along more than 100 μm length of the transduced PC layer. The average number of aggregates in a 100 μm length of the PC layer was significantly decreased by the expression of CRAG by IDLVs (3.9 ± 0.6 aggregates, P o0.001), as well as by WTLVs (6.6 ± 0.7 aggregates, P o 0.001), compared with noninjected control SCA3 mice (15.9 ± 1.9 aggregates) (Figure 4o ).
DISCUSSION
In this study, we examined the time course of transgene expression by IDLVs in mouse PCs in vivo and assessed the usability of IDLVs for the treatment of SCAs compared with WTLVs using SCA model mice. Two months after the injection of IDLVs expressing GFP, the fluorescence intensity and expression levels of the mRNA in the PC somata were approximately the same as those after the WTLV injection. However, both GFP fluorescence and mRNA levels in IDLV-treated cerebella were significantly decreased at 6 and 12 months after the viral injection. The levels of GFP mRNA in IDLV-treated cerebella were approximately 25% and 5% of those in WTLV-treated cerebella at 6 and 12 months after the injection, respectively. Cerebellar injection of IDLVs expressing CRAG significantly rescued the rotarod performance of SCA3 mice with a time course almost identical to the injection of WTLVs. The performance of SCA3 mice treated with WTLVs was significantly better up to 6 months after the injection, but it became worse thereafter and was indistinguishable from the noninjected control SCA3 mice at 12 months after the injection. Notably, the better performance of SCA3 mice that expressed CRAG from IDLVs continued even 12 months after the injection.
We showed that IDLVs with a mutant gene encoding the D64V integrase had approximately 100 times less ability to integrate the proviral genome into the chromosome of cerebellar neurons in vivo compared with WTLVs. This result suggests that the IDLVs have a much lower chance of insertional mutagenesis, which can The rotarod performances of non-injected SCA3 mice (non-injected, n = 7 mice) were compared with those of SCA3 mice injected with WTLVs expressing GFP-P2A-CRAG (+WTLV-CRAG, n = 5), IDLVs expressing GFP-P2A-CRAG (+IDLV-CRAG, n = 5) or IDLVs expressing GFP alone (+IDLV-GFP, n = 5). SCA3 mice injected with IDLVs expressing GFP-P2A-CRAG, but not those injected with IDLVs expressing GFP alone, significantly improved their rotarod performances up to 12 months after the injection compared with the non-injected SCA3 mice. SCA3 mice treated with WTLVs expressing GFP-P2A-CRAG also improved their performance at 2 and 6 months, but not at 12 months, after the injection. *P o0.05, **P o0.01, ***P o0.001 (vs non-injected SCA3 mice), † P o0.05 and † † Po0.01 (vs SCA3 mice expressing GFP alone) by one-way analysis of variance (ANOVA) followed by Tukey's post hoc test.
Efficacy of integrase-defective lentivral vectors H Saida et al cause substantial adverse effects. Although the ratio of integration by IDLVs relative to WTLVs was 1/100, IDLVs caused a robust transgene expression in PCs. The expression levels of a transgene were approximately the same as WTLVs at 2 months after injection and declined thereafter.
A previous study showed more efficient human immunodeficiency virus integration in stimulated T cells than in quiescent T cells because of the slower viral life cycle in quiescent cells: human immunodeficiency virus integration peaks 24 h after infection in stimulated cells, whereas it begins 36 h after infection in quiescent cells. 18 The long-terminal repeat ends of the reversetranscribed viral DNA in the resting cells have higher chances of degradation or processing by cytoplasmic enzymes and the degraded viral DNAs are less efficiently integrated into the host chromosome. 18 Similarly, it is reasonably considered that the integrase-mediated insertion by WTLVs occurs more efficiently in actively dividing HeLa cells than in quiescent neurons in vivo, whereas the integrase-independent insertion by cellular recombination enzymes occurs at a similar frequency in HeLa cells and in neurons. In contrast, IDLVs lack the integrase-dependent integration and only show the residual integrase-independent insertion to a similar degree with WTLVs. 11, 19 Thus, higher integrasemediated insertion by WTLVs in HeLa cells than in neurons and a similar frequency of the integrase-independent insertion by WTLVs with that by IDLVs in HeLa cells and neurons could explain the substantial difference in the integration efficiency of IDLVs relative to WTLVs between HeLa cells (1/3850) and neurons in vivo (1/111) (Figures 1e and f) .
Injection of WTLVs expressing CRAG into the SCA3 mouse cerebella significantly improved their rotarod performance, but (a-l) Cerebellar slices from SCA3 mice injected with WTLVs (middle panels) or IDLVs (right panels) expressing GFP-P2A-CRAG and those from non-injected SCA3 mice (left panels) were produced at 12 months after the viral injection. The slices were triple immunostained for GFP (a-c), and HA-tagged mutant ataxin-3 (d-f) and calbindin (g-i). The merged images were presented in the lowest panels (j-l). (m) Number of PCs per 100 μm length of the PC layer in slices from non-injected SCA3 mice and mice injected with WTLVs or IDLVs expressing GFP-P2A-CRAG. (n) Number of GFPpositive PCs per 100 μm length of the PC layer in slices from non-injected SCA3 mice and mice injected with WTLVs or IDLVs expressing GFP-P2A-CRAG. (o) Number of mutant ataxin-3 aggregates per 100 μm length of the PC layer in slices from non-injected SCA3 mice and mice injected with WTLVs or IDLVs expressing GFP-P2A-CRAG. ***P o0.001 by Tukey's post hoc test after one-way analysis of variance (ANOVA). NS, not significant. Scale bar, 100 μm.
Efficacy of integrase-defective lentivral vectors
H Saida et al the improved condition did not last long, and the performance returned to a level approximately the same as that of non-injected SCA3 mice. In contrast, IDLV-treated SCA3 mice showed a significantly better performance even at 12 months after the injection. We did not expect these results, as robust transgene expression continued more than 1 year in WTLV-infected cells in vivo, whereas the expression in IDLV-infected cells significantly regressed ( Figure 2) . Overall, the decline of the rotarod performance after 6 months may be explained by the extensive degeneration of PCs in non-transduced lobules, eventually leading to the deterioration of cerebellar function. The reason that explains the inferiority of WTLVs to IDLVs in rotarod performance is not clear, but one possibility is that the continuous overexpression of CRAG and GFP in the WTLV-infected PCs potentiated the endoplasmic reticulum (ER) stress, as the SCA3 mouse PCs are susceptible to the ER stress because of high levels of mutant ataxin-3 expression in PCs. In IDLV-infected PCs, the toxic aggregates were removed by transiently expressed CRAG. Once toxic aggregates are removed in SCA patients, it takes an extended period of time, possibly many years, for the reaccumulation; thus, transient CRAG expression by IDLVs may produce a better therapeutic outcome than continuous CRAG expression, which could enhance the ER stress of affected neurons. Another problem of using lentiviral vectors for gene therapy is the difficulty in controlling the expression levels of a therapeutic gene. To gain a better and sufficient therapeutic efficacy, the expression levels should fall within a therapeutic window. However, the overexpression of a therapeutic protein could affect cellular function by excessive amounts of the protein itself and/or occupying the cellular protein synthesis machinery by the production of the therapeutic protein (and eventually the suppression of endogenous protein production). 20 Even if such adverse effects are observed, there is currently no way to remove integrated proviruses from host chromosomes. Accommodation of the doxycycline-inducible system in the lentiviral main plasmid may be effective for controlling a transgene expression; [21] [22] [23] however, the long-term use of antibiotics, such as doxycycline, also causes significant unwanted effects in patients. 24 Recently, adeno-associated virus (AAV) vectors have been widely used as gene therapy vectors because of their nonpathogenicity and efficient gene transfer potential. [25] [26] [27] However, similar to lentiviral vectors, high levels of transgene expression by AAV vectors also continue for more than several years at minimum. 28, 29 In contrast, transgene expression by adenoviral vectors lasts only for a few months in the brain. 30 Although the declining speed of transgene expression by adenoviral vectors may be faster than that by IDLVs, adenoviral vectors have far greater tropism for glial cells than for neurons and exhibit very low transduction efficacy in neurons, [30] [31] [32] which may become a problem when gene delivery is targeted to neurons. Moreover, adenoviral vectors have significant immunogenicity, 27,33 which could cause significant damage in infected cells. Thus, IDLVs are thought to be safe from the point of minimum immunogenicity and spontaneous reduction of transgene expression, the latter of which is supposed to initiate several months after viral infection in the brain.
Neurodegenerative diseases, including the major types of SCAs, are caused by the abnormal accumulation of toxic proteins. [34] [35] [36] The onset of these diseases occurs, in many cases, during the third or fourth decade of life 34, 36 because the disease-causing proteins are degraded through the ubiquitin-proteasome pathway and autophagy in younger individuals. [37] [38] [39] As individuals become older, the capacity of degrading unnecessary proteins in neurons is exacerbated, leading to a gradual accumulation of the abnormal proteins. Thus, it requires a long period before disease-causing proteins sufficiently accumulate in neurons to impair neuronal functions and for symptoms to emerge. Here, using SCA3 model mice, we showed that a therapeutic protein, CRAG, could be efficiently expressed in cerebellar neurons in vivo by IDLVs, which facilitated the degradation of toxic protein aggregates in PCs. Although the IDLV-mediated expression of the therapeutic protein almost disappears within 1-year after injection, it is thought that it takes an extended period before the disease-causing proteins accumulate again to produce a re-emergence of symptoms in patients. Therefore, IDLVs may essentially be as effective as WTLVs and safer than WTLVs in treating neurodegenerative diseases. Further studies using large animals, such as non-human primates, will warrant the future clinical application of IDLVs.
MATERIALS AND METHODS Animals
Wild-type C57BL/6 mice were purchased from Japan SLC (Shizuoka, Japan). SCA3 model mice that expressed truncated ataxin-3 with a 69 polyglutamine stretch in PCs were previously generated in our laboratory. 16 Heterozygous SCA3 mice were maintained on a C57BL/6J genetic background by intercrossing fertile wild-type mice in our breeding colony at the Institute of Experimental Animal Research, Gunma University Graduate School of Medicine (Maebashi, Gunma, Japan). Both sexes were used in the experiments. All procedures for the care and treatment of animals were performed according to the Japanese Act on the Welfare and Management of Animals and the Guidelines for Proper Conduct of Animal Experiments issued by the Science Council of Japan. The experimental protocol was approved through the Institutional Committee of Gunma University (No. 09-062). All efforts were made to minimize suffering and reduce the number of animals used.
Plasmids and virus preparation
Human immunodeficiency virus-derived lentiviral vectors, which were pseudotyped with the VSV-G, were used in this study. The lentiviral vector plasmid DNAs were kindly provided by Dr Nienhuis (St Jude Children's Research Hospital, Memphis, TN, USA). The backbones of helper plasmids were derived from pCAGGS. 40 The vectors were designed to express GFP or GFP-P2A-3 × Flag-tagged CRAG under the control of the MSCV promoter. The lentiviral vectors were produced as described previously. 41 Briefly, four plasmids consisting of pCL20c, pCAGkGP1R, pCAG4RTR2 and pCAGVSV-G were co-transfected into HEK293T cells (Thermo Fisher Scientific, Kanagawa, Japan) using the calcium phosphate method. After 48 h, the supernatant containing viral particles was harvested and ultracentrifuged (CP80WX; Hitachi Koki, Tokyo, Japan). The precipitated viral particles were resuspended in 70 μl of Dulbecco's phosphate-buffered saline (− ). The genome titers of WTLVs and IDLVs were determined using a known titer samples as a standard, except for lentiviral vectors expressing GFP-P2A-3 × Flag-tagged CRAG. To confirm that the titers of WTLVs expressing GFP-P2A-3 × Flag-tagged CRAG were therapeutically effective, that is, the titers were equal or higher than those used in our previous experiments, 16 the biologic titers (transduction units ml
) were determined by counting the number of GFP-expressing cells after transducing HEK293T cells, as described. 41 The lentiviral solution was stored at 4°C and used within 2 weeks.
Western blot analysis
Viral solutions were solubilized with lysis buffer containing 50 mM phosphate buffer (pH 7.4) and 2% (w v − 1 ) sodium dodecyl sulfate. Solubilized solutions were added with the same volume of sample buffer, which contained 125 mM Tris-HCl (pH 6. ) bromophenol blue and were incubated for 25 min at 55°C. Samples were electrophoresed on sodium dodecyl sulfate-polyacrylamide gels (5-15%) and transferred to nitrocellulose membranes (BioTrace NT Nitrocellulose Transfer Membrane; PALL Co., Port Washington, NY, USA). The membranes were blocked with 5% non-fat skimmed milk in phosphate-buffered saline containing 0.05% Tween-20. The immunoreaction was performed with rabbit polyclonal anti-VSV-G antibodies (1:4000; Sigma), followed by the incubation of horseradish peroxidase-conjugated anti-rabbit IgG (Bio-Rad, Tokyo, Japan) at a 1:40 000 dilution. Immunoreactive bands were visualized using an enhanced chemiluminescence reagent (Clarity Western ECL Substrate; Bio-Rad). The relative amount of immunoreactive VSV-G band in each lane was quantified with ImageJ software (http://rsb.info.nih.gov/ij/).
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Viral injection into mouse cerebellum
Mice were anesthetized before and throughout the viral injection using 2% isoflurane inhalation (flow speed: 1 l min − 1 ) with the mouse mounted on a stereotactic frame. A burr hole was drilled on the surface of the cerebellar vermis, which was located 5-6 mm caudal to the bregma. The blunt-ended tip (33 G) of a Hamilton syringe attached to a micropump (UltramicroPump II; World Precision Instruments (WPI), Sarasota, FL, USA) was placed immediately below the pia mater of the cerebellar vermis. Ten microliters of viral solution was injected at a rate of 300 nl min − 1 . The temporal change of a transgene expression after IDLV or WTLV infection in mouse cerebellum in vivo (Figure 2 ) was examined using 29 mice. The therapeutic effect of CRAG expression by IDLVs or WTLVs (Figure 3 ) was explored using 34 mice.
Quantitative Alu-PCR
To purify the chromosomal DNA from HeLa cells, the cells were seeded on a 6-cm culture dish at a density of 1 × 10 5 cells in the medium, which contained 1 μl of WTLVs or the same volume of genomic titer-adjusted IDLVs and Polybrene (final concentration: 6 μg ml − 1 ). Four days after cultivation, HeLa cells were collected using a plastic scraper after washing with ice-cold PBS. HeLa cells without viral infection were used as negative controls. Chromosomal DNA was purified using a Genomic DNA Purification System (A2361; Promega, Madison, WI, USA). The integrated transgene was detected by nested Alu-PCR. The details of the Alu-PCR protocol have been described in a previous report. 42 The first PCR was carried out using a forward primer that was targeted to the long-terminal repeat from the retroviral sequence (LM-667, 5′-ATGCCACGTAAGCGAAACT CTGGCTAACTAGGGAACCCACTG-3′), which was attached to a lambda phage-specific heel sequence at the 5′ side; this method was used to avoid amplification of the non-integrated transgene derived from the lentiviral vector, as well as one-long-terminal repeat or two-long-terminal repeat circular DNA. Reverse primers were targeted to the Alu sequences present in the host genomic DNA (Alu1, 5′-TCCCAGCTACTGGGGAGGCTGAGG-3′; Alu2, 5′-GCCTCCCAAAGTGCTGGGATTACA-3′). The first reaction was performed using PrimeStar Max (Takara Bio, Shiga, Japan) with three primers, including LM-667, Alu1 and Alu2, in 20 μl of reaction volume. The thermal cycler was programmed to perform a hot start at 98°C for 10 s, 60°C for 5 s and 72°C for 2 min. The second real-time quantitative PCR was performed using 2 μl of the first PCR product. The reactions were performed using SYBER Premix EX Taq II (Takara Bio) with the addition of two nested primers (LambdaT, 5′-ATGCCACGTAAGCGAAAC T-3′, and AA55M, 5′-GCTAGAGATTTTCCACACTGACTAA-3′) in 25μl of reaction volume. The real-time PCR was conducted using a Thermal Cycler Dice TP800 (Takara Bio) with a hot start at 95°C for 10 s, followed by 40 cycles of 95°C for 5 s and 60°C for 30 s. The following glyceraldehyde 3-phosphate dehydrogenase primers were used for normalization in the second PCR: forward, 5′-TGTGTCCGTCGTGGATCTGA-3′ and reverse, 5′-TTGCTGTTGAAG TCGCAGCAG-3′.
Quantitative B1-PCR
To investigate the efficiency of the proviral integration into the mouse brain, we used a mouse B1 sequence, 43 instead of a human Alu sequence. 44 The mouse B1 sequence is a homologous repeat sequence of the human Alu sequence, and these sequences belong to short interspersed elements. 45 Ten microliters of WTLVs or the same volume of IDLVs were injected into the cerebellar vermis of P27-28 mice (n = 5 mice, respectively). One week after the injection, the GFP-expressing cerebellar vermis was excised from the whole cerebellum under a fluorescence microscope. Then, the tissue was homogenized immediately in the lysis buffer containing proteinase K. After overnight incubation at 60°C, genomic DNAs were harvested using the phenol-chloroform and ethanol precipitation method. The genomic samples were finally diluted to 10-15 ng μl − 1 with TE buffer and used for PCR analysis. The procedure for the nested B1-PCR was essentially the same as for the nested Alu-PCR. The first PCR was performed using KOD FX Neo (Toyobo, Osaka, Japan) and three different primers. One primer was a lambda phage sequence-tagged GFP forward primer (5′-ATGCCACGTAAGCGAAACTCGACCACTACCAGCAG AACAC-3′), whereas the others were sense and antisense primers targeted to the B1 sequence (sense, 5′-TCTACAAAGTGAGTTCCAGGACAGCCAGGG-3′ and antisense, 5′-CCCTGGCTGTCCTGGAACTCACTTTGTAG-3′). The thermal cycler was programmed to perform 20 cycles of 98°C for 10 s, 60°C for 30 s and 68°C for 5 min. The first PCR products were diluted 100-fold and used as a template for the second real-time PCR. The second real-time PCR was performed using a KAPA SYBR FAST qPCR Kit (Nippon Genetics, Tokyo, Japan) and paired primers targeted to the lambda phase tag (5′-ATGCCACGTAAGCGAAACT-3′) and the GFP sequence (5′-TGTGATCG CGCTTCTCGTTGG-3′). The real-time PCR was performed at 45 cycles of 95°C for 3 s and 60°C for 30 s. Glyceraldehyde 3-phosphate dehydrogenase was used to normalize the variation derived from the difference in each sample volume.
Quantitative reverse transcriptase-PCR
The amount of genomic RNA in lentiviral particles and that of mRNA of GFP expressed in mouse cerebellum were examined by quantitative reverse transcriptase-PCR. Total RNA was extracted using a RNA isolation kit (RNeasy Mini kit; Qiagen, Hilden, Germany) and reverse transcribed with the ReverTra Ace qPCR RT kit (Toyobo). The quantitative reverse transcriptase-PCR was performed using a THUNDERBIRD SYBR qPCR Mix (Toyobo) with the addition of the following primer sets: amplification of the viral genome containing the MSCV promoter, MSCV-F, 5′-CACTCCCTTA AGTTTGACCTT-3′ and MSCV-R, 5′-GCCAAGGCTTCCCAGGTC-3′, and the amplification of the GFP gene from mouse cerebellum, GFP-F, 5′-CGACCAC TACCAGCAGAACAC-3′ and GFP-R, 5′-TGTGATCGCGCTTCTCGTTGG-3′. The PCR was performed for 40 cycles consisting of 95°C for 5 s followed by 60°C for 30 s. Glyceraldehyde 3-phosphate dehydrogenase was used to normalize the variation derived from the difference in each sample volume.
Rotarod test
The motor control ability of SCA3 mice was assessed by a rotarod (Muromachi Kikai, Tokyo, Japan) with two different paradigms. In the accelerated paradigm, the rod accelerated from 0 to 40 r.p.m. in 3 min, whereas in the stable speed paradigm, the rod rotated at a stable speed of 5 r.p.m. Mice were assessed with both paradigms immediately before and 2, 6 and 12 months after the viral injection. In the accelerating and stably rotating tests, mice were subjected to four and six trials, respectively, with a 30 min rest between the trials. The average latency to fall from the rod was examined. Seven non-injected control mice and five lentivirally treated mice from each group were examined.
Immunohistochemistry
Mice were transcardially perfused with 4% paraformaldehyde in 0.1 M phosphate buffer after they were anesthetized with a combination of ketamine (100 mg kg − 1 body weight) and xylazine (10 mg kg − 1 body weight). The brains were then postfixed in the same fixative for 24 h. For immunostaining, the cerebellum was cut into 50 μm sagittal sections using a microslicer (VT1000S; Leica, Nussloch, Germany). Floating sections were immunostained with rabbit polyclonal anti-GFP antibody (1:500; Frontier institute, Hokkaido, Japan), rat monoclonal anti-HA (1:500; Roche, Basel, Switzerland) and mouse monoclonal anti-calbindin D-28K (1:500; Swant, Bellinzona, Switzerland) and visualized with Alexa Fluor 488-conjugated anti-rabbit IgG, Alexa Fluor 568-conjugated anti-rat IgG and Alexa Fluor 680-conjugated anti-mouse IgG (1:1000; Life Technologies, Carlsbad, CA, USA).
Confocal microscopy
Photographs of the whole brain were obtained by fluorescent stereoscopic microscopy (VBG25; Keyence, Osaka, Japan). The brains from lentivirally treated or non-treated mice (n = 3 mice from each group) were then postfixed in the same fixative for 24 h. The cerebellum was cut into 50-μm sagittal sections using a microslicer (VT1000S; Leica). Immunohistochemical images were obtained by a confocal laser-scanning microscope (LSM 5 PASCAL; Zeiss, Oberkochen, Germany). Serial confocal scanning images were obtained using optical sectioning with 1 μm slices and were reconstructed three dimensionally. Sizes of ataxin-3 aggregates in PCs were assessed with Image Analysis Software (WinROOF; Mitani Corporation, Fukui, Japan).
Measurement of GFP fluorescence intensity in PC somata
Native GFP fluorescence images of the cerebellar cortex ( Figure 2 ) were taken with a confocal microscope. For comparison of GFP fluorescence intensity between different animals, the images were always obtained with the same condition. In each experimental group, more than 100 PCs from three mice were measured with Image Analysis Software (WinROOF).
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